Literature DB >> 3123260

Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains.

S R Heard1, B Wren, M J Barnett, J M Thomas, S Tabaqchali.   

Abstract

Two hundred and forty-eight patients from shared oncology and general medical wards were prospectively studied over a 6-month period for carriage of Clostridium difficile during an outbreak of clinical disease with an epidemic strain of the organism. Risk factors for infection were assessed. Acute leukaemia and/or its treatment were identified as significantly increasing the risk of infection. The relationship between the type of C. difficile isolated (as defined by a typing system based on the incorporation of [35S]methionine into bacterial proteins followed by gel electrophoresis), the presence of faecal toxins A and B and clinical symptoms were analysed. Carriage of the epidemic strain, type X, had a significant association with symptoms amongst oncology patients, with two thirds of these patients having detectable faecal toxin A and one third detectable faecal toxin B. During an outbreak of C. difficile-associated disease, typing the organism and assaying for both faecal toxins in symptomatic patients may be of benefit in determining which patients require specific, urgent treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123260      PMCID: PMC2249202          DOI: 10.1017/s0950268800065560

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  19 in total

1.  Relapsing pseudomembranous colitis associated with cancer chemotherapy.

Authors:  V Fainstein; G P Bodey; R Fekety
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

2.  Spread of Clostridium difficile among patients receiving non-absorbable antibiotics for gut decontamination.

Authors:  T R Rogers; M Petrou; C Lucas; J T Chung; A J Barrett; S P Borriello; P Honour
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-08

Review 3.  Pseudomembranous colitis: pathogenesis and therapy.

Authors:  F J Tedesco
Journal:  Med Clin North Am       Date:  1982-05       Impact factor: 5.456

4.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

5.  Faecal toxin and severity of antibiotic-associated pseudomembranous colitis.

Authors:  D W Burdon; R H George; G A Mogg; Y Arabi; H Thompson; M Johnson; J Alexander-Williams; M R Keighley
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

6.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.

Authors:  M R Keighley; D W Burdon; Y Arabi; J A Williams; H Thompson; D Youngs; M Johnson; S Bentley; R H George; G A Mogg
Journal:  Br Med J       Date:  1978-12-16

7.  Selective and differential medium for isolation of Clostridium difficile.

Authors:  W L George; V L Sutter; D Citron; S M Finegold
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

8.  Method for the typing of Clostridium difficile based on polyacrylamide gel electrophoresis of [35S]methionine-labeled proteins.

Authors:  S Tabaqchali; S O'Farrell; D Holland; R Silman
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

9.  Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis.

Authors:  K H Kim; R Fekety; D H Batts; D Brown; M Cudmore; J Silva; D Waters
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  9 in total

1.  Molecular studies on the epidemiology and pathogenicity of Clostridium difficile.

Authors:  S Tabaqchali
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

2.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients.

Authors:  David B Stewart; Emmanuel Yacoub; Junjia Zhu
Journal:  J Gastrointest Surg       Date:  2012-06-13       Impact factor: 3.452

4.  Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county.

Authors:  T Norén; T Akerlund; E Bäck; L Sjöberg; I Persson; I Alriksson; L G Burman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Investigation and management of Clostridium difficile colonisation in a paediatric oncology unit.

Authors:  I Schuller; V Saha; L Lin; J Kingston; T Eden; S Tabaqchali
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

6.  A case of pseudomembranous colitis after voriconazole therapy.

Authors:  Jae-Cheol Kwon; Min-Kyu Kang; Si-Hyun Kim; Su-Mi Choi; Hee-Je Kim; Woo-Sung Min; Dong-Gun Lee
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

7.  Excess Mortality Attributable to Clostridium difficile and Risk Factors for Infection in an Historic Cohort of Hospitalised Patients Followed Up in the United Kingdom Death Register.

Authors:  Mark Reacher; Neville Q Verlander; Iain Roddick; Cheryl Trundle; Nicholas Brown; Mark Farrington; Philip Jones
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

8.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

9.  Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches.

Authors:  Nan Lan; Jean Ashburn; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.